Skip to main content
SMTI
NASDAQ Industrial Applications And Services

Sanara MedTech to Be Acquired by MiMedx in $35/Share Cash-and-Stock Deal

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
10
Price
$30.25
Mkt Cap
$277.21M
52W Low
$16.047
52W High
$35.95
52W Position info
89% above low
Off High info
16% below high
Rel. Volume info
4.5× avg
Market data snapshot near publication time

SMTI sits 89% above its 52-week low of $16.047 on elevated volume (4.5× avg).

Summary

Sanara MedTech will be acquired by MiMedx Group for $33.00 cash and 0.4735 MiMedx shares per Sanara share, a total value of $35 per share. The deal creates a leading regenerative medicine company and is expected to close by end of 2026.


Key Events · M&A and Partnerships · SMTI

  • Definitive Merger Agreement Signed

    Sanara has entered into a definitive agreement to be acquired by MiMedx Group, Inc. for $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share, implying a total value of $35 per share based on MiMedx's 5-day average price of $4.22.

  • Transaction Value and Premium

    The deal values Sanara at an enterprise value of approximately $350 million and represents a 46% premium to Sanara's 30-day volume-weighted average price as of July 28, 2026.

  • Shareholder Lock-Up Secured

    Stockholders holding approximately 38.9% of Sanara's voting power have entered into voting agreements to support the merger, significantly de-risking the shareholder approval process.

  • Strategic Rationale and Synergies

    The combination is expected to nearly double MiMedx's surgical revenue, create a combined company with over $400 million in 2027 revenue and 20%+ adjusted EBITDA margins, and generate over $20 million in run-rate cost synergies.


Analysis · SMTI · Industrial Applications And Services

In a deal that reshapes its standalone future, Sanara MedTech has agreed to be acquired by MiMedx Group through a cash-and-stock transaction valuing Sanara at $35 per share—a 46% premium to its 30-day VWAP. The merger unites two regenerative medicine companies, nearly doubling MiMedx's surgical revenue and creating a platform with expected 2027 revenue exceeding $400 million. Under the terms, Sanara shareholders will receive $33.00 in cash and 0.4735 MiMedx shares per Sanara share, with the stock component valued at $2.00 based on MiMedx's recent average price. Both boards have unanimously approved the transaction, which is expected to close by year-end, pending Sanara shareholder approval and regulatory clearances.

At the time of this filing, SMTI was trading at $30.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $277.2M. The 52-week trading range was $16.05 to $35.95. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SMTI - Latest Insights

SMTI
Jun 04, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.12
Real-time Price: $32.75 info
Change: +$10.63 (+48%) info
Market Cap: $277.21M info
SMTI
May 12, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.44
Real-time Price: $32.75 info
Change: +$12.31 (+60%) info
Market Cap: $277.21M info
SMTI
May 11, 2026, 5:21 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $19.22
Real-time Price: $32.75 info
Change: +$13.53 (+70%) info
Market Cap: $277.21M info
SMTI
May 11, 2026, 4:51 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $17.81
Real-time Price: $32.75 info
Change: +$14.94 (+84%) info
Market Cap: $277.21M info
SMTI
Mar 24, 2026, 4:02 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $18.08
Real-time Price: $32.75 info
Change: +$14.67 (+81%) info
Market Cap: $277.21M info